Indaptus And BeiGene Collaborates For Cancer Treatment Trial Combining Decoy20 And PD-1 Inhibitor

Indaptus Therapeutics, Inc., a clinical-stage biotech company developing novel treatments for cancer and viral infections, has announced a clinical supply agreement with BeiGene. This partnership builds on preclinical findings where Indaptus' Decoy20, combined with a PD-1 inhibitor, led to complete cancer regression and immune memory in animal models. The agreement will facilitate human trials evaluating the combination of Decoy20 and BeiGene's PD-1 inhibitor, tislelizumab, designed to trigger a broad immune response against cancer.

Decoy20 is being read up for its capability to treat a variety of liver, colon, and pancreatic cancers. In preclinical preliminaries, joining Decoy20 with a PD-1 inhibitor and an oral non-steroidal anti-inflammatory drug brought about 80-100 percent cancer destruction rates. Indaptus anticipates finding a combination therapy to enhance similar outcomes in humans.

Jeffrey Meckler, CEO of Indaptus Therapeutics, said in a statement, “PD-1 inhibitors have proven to be meaningful in treating multiple types of cancer. We are optimistic that we can improve outcomes by broadly and safely stimulating the immune system in a way that could enhance the overall effectiveness of currently approved cancer treatments.”

He also said, “This agreement with BeiGene marks a significant step forward in the search for curative cancer treatments for some of the most challenging cancers. Additionally, we view this as a significant milestone for Indaptus.”

BeiGene will provide tislelizumab and technical expertise through the agreement to accelerate the clinical trial process by combining two investigational drugs. Decoy20 employs Indaptus' "Pulse-Prime" approach, designed to enhance the immune response while causing minimal and manageable side effects.

“Decoy20’s ability to synergize with various approved therapeutic modalities, including checkpoint therapy, makes it a promising partner for several novel combination approaches. This trial could reshape the checkpoint therapy landscape, as it will be the first time a short but broadly acting agent such as Decoy20, utilizing our innovative Pulse-Prime approach, will be tested in combination with a PD-1 inhibitor," said Dr. Michael Newman, Founder and Chief Scientific Officer at Indaptus.

Indaptus plans to seek FDA approval to initiate the combination trial, with the first clinical study expected to start in 2025. The company will host a conference call today at 4:30 p.m. ET to discuss this development and answer questions.